Research programme: CCR5 antagonists - TakedaAlternative Names: TAK-779
Latest Information Update: 14 Mar 2007
At a glance
- Originator Takeda
- Class Small molecules
- Mechanism of Action CCR5 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 31 Mar 2003 Preclinical trials in HIV infections treatment in Japan (PO)